Evidence map›Paper›PMID 36123678›Full record

ArticleBMC pulmonary medicine2022

EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.

Zhenxiang Li, Qing Zhou, Qi Wang, Haiyong Wang, Weiming Yue

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Zhenxiang LiMedical Integration and Practice Center, Shandong University, Jinan, China.
Qing ZhouHospital of Traditional Chinese Medicine of Liaocheng City, Liaocheng, China.
Qi WangShandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Haiyong WangMedical Integration and Practice Center, Shandong University, Jinan, China. wanghaiyong6688@126.com.
Weiming YueDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China. yueweiming2008@126.com.
Shandong University · CNLiaocheng People's Hospital · CNQilu Hospital of Shandong University · CNShandong Tumor Hospital · CN

Funding

Academic Promotion Programme of Shandong First Medical University 2019RC004Taishan Scholars Project tsqn201812149
6 · The paper itself

Abstract

backgroundThe aim of the study was to investigate predictive value of gene mutation for atezolizumab treatment response from OAK and POPLAR cohorts.

methodsSeveral public databases were used for analyzing gene mutation type of EPHA5 and association with alterations of other genes. Survival analysis was performed for patients receiving atezolizumab from OAK and POPLAR cohorts.

resultsEPHA5 mutation have high frequency to harbor TP53 and KEAP1 mutations. The bTMB value has significant difference between EPHA5 mutant and wild-type cases. Patients with EPHA5 mutation got worse survival compared to those without gene mutations receiving atezolizumab (P = 0.0186).

conclusionsEPHA5 mutant NSCLC may represent a subpopulation which showed worse response after treatment of atezolizumab compared to wild-type ones.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedBiomarkers, TumorHumansKelch-Like ECH-Associated Protein 1MutationNF-E2-Related Factor 2Receptor, EphA5Antibodies, Monoclonal, HumanizedatezolizumabBiomarkers, TumorEPHA5 protein, humanKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Receptor, EphA5BiomarkersImmunologyLung cancerNon-small cell lung cancer

Identifiers

PMID36123678
PMCPMC9487080
OpenAlexW4296293145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.